2023-04-12 08:35:13 ET
- Denali Therapeutics ( NASDAQ: DNLI ) added ~3% pre-market Wednesday in reaction to Biogen’s ( NASDAQ: BIIB ) decision to excise an option to license the company’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:A?).
- The transaction follows the recent advancement in the development of A?-directed therapeutic antibodies against Alzheimer’s disease, Chief Scientific Officer of Denali ( DNLI ) Joseph Lewcock noted.
- “Our ATV:A? program is designed to safely increase exposure of the therapeutic antibody in the brain and potentially lead to improved efficacy and/or safety,” Lewcock added.
- Following the transaction, Denali ( DNLI ) is entitled to a one-time option exercise payment in addition to development and commercial milestone payments and royalties based on future net sales.
- The option exercise is part of a collaboration the two companies announced in 2020.
For further details see:
Biogen licenses amyloid beta-related program from Denali